.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Active surveillance (AS) is an essential strategy for managing localized prostate cancer. Specifically, it allows selected men to defer invasive treatment. However, clinicians require precise tools to monitor patients effectively. Recently, researchers developed the AI-GUR risk score to address this diagnostic challenge. Because of its advanced design, this digital pathology tool predicts Gleason grade group (GGG) upgrading with high accuracy.
The development of the AI-GUR model initially involved training on 998 biopsies. Subsequently, investigators validated the results in an independent cohort. Consequently, the findings demonstrated that the score significantly predicts GGG reclassification. For instance, the model achieved an odds ratio of 1.60. Furthermore, the analysis showed that the tool identifies risks that traditional clinicopathologic parameters often miss. Additionally, the predictive power remained consistent across various time intervals. As a result, the tool seems to detect initial biopsy errors rather than late progression.
Notably, the AI-GUR risk score provides data that exceeds the utility of the CAPRA score. While conventional methods are useful, they often lack sufficient detail. Therefore, urologists can use this AI tool to refine patient selection for surveillance. In addition, the score uses existing biopsy specimens, meaning no extra procedures are required. In contrast to manual reviews, the AI provides an objective and standardized assessment. Simultaneously, it complements molecular testing to offer a comprehensive risk profile.
In conclusion, digital pathology AI is transforming prostate cancer management. Because this technology offers individualized risk estimates, it improves shared decision-making. Moreover, clinicians can now identify high-risk candidates earlier than ever before. Thus, the implementation of such tools could significantly reduce treatment morbidity. Ultimately, the AI-GUR represents a major advancement in precision urology.
The AI-GUR risk score is a digital pathology AI tool that estimates the probability of Gleason grade group (GGG) upgrading in patients eligible for active surveillance, based on histopathology images from diagnostic biopsies.
It identifies patients at high risk of grade upgrading early, allowing urologists to adjust monitoring intensity or recommend curative treatment sooner than traditional risk stratification tools would allow.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Mabey B et al. Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance. Future Oncol. 2026 Jun 16. doi: 10.1080/14796694.2026.2686438. PMID: 42299723.
Bulten W et al. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Lancet Oncol. 2022;23(1):84-95.
Egevad L et al. Digital pathology and artificial intelligence in prostate cancer. J Intern Med. 2022;291(4):428-444.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The AI-GUR (Artificial Intelligence-Gleason Upgrade Risk) score is a new digital pathology AI tool that predicts Gleason grade group upgrading in prostate cancer patients on active surveillance, outperforming traditional risk stratification methods like the CAPRA score.
2 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
